Author: Jane Edwards|| Date Published: September 12, 2018
Four companies have each won a potential five-year, $75M contract to provide the Food and Drug Administration™s center for biologics evaluation and research with data, tools and infrastructure for use in the surveillance of vaccines, tissues, blood products and other biologics.
The contractors will provide the FDA with œindirect access to a network of electronic health records and other data of U.S. patients through a distributed data framework and build a data infrastructure to help the agency run observational studies and queries related to CBER-regulated biologics, according to the solicitation.
The BEST initiative also includes the development of semi-autonomous methods to facilitate reviews of medical charts.
The indefinite-delivery/indefinite-quantity contracts cover three other tasks: queries and epidemiological studies; operations and management; and outreach and communications, according to the statement of work.
Brian Meyer, federal field chief technology officer at Axonius Federal, said cybersecurity asset management could help government agencies make dozens…
“Technology transformation company Red River has acquired Invictus International Consulting to expand its cybersecurity and enterprise modernization capabilities to support…
Synergy ECP, a software engineering, cybersecurity and systems engineering services provider, has acquired NetServices, a company offering secure, mission-focused technology services. The…
Precision Aerospace & Defense Group and FACT II Acquisition, a special purpose acquisition company, have signed a definitive business combination agreement to…
LMI has announced the acquisition of intellectual property and advanced capabilities to broaden its in-transit visibility and asset tracking services for…
Four companies have each won a potential five-year, $75M contract to provide the Food and Drug Administration™s center for biologics evaluation and research with data, tools and infrastructure for use in the surveillance of vaccines, tissues, blood products and other biologics.
